Evolocumab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia

Trial Timeline

Mar 24, 2016 → Nov 25, 2019

NCT ID

NCT02392559

About Evolocumab + Placebo

Evolocumab + Placebo is a phase 3 stage product being developed by Amgen for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02392559. Target conditions include Heterozygous Familial Hypercholesterolemia.

What happened to similar drugs?

1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (1) Active (13)

✅PraluentSanofiApproved

🔄AZD0780 + PlaceboAstraZenecaPhase 3

🔄Anacetrapib + Placebo for anacetrapibMerckPhase 3

🔄InclisiranNovartisPhase 3

🔄Inclisiran + PlaceboNovartisPhase 3

🔄FluvastatinNovartisPhase 3

🔄Inclisiran + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06081153	Phase 1	Recruiting	Jul 1, 2026	Feb 28, 2028	Abdominal Aortic Aneurysm
NCT03872401	Phase 3	Completed	Jun 11, 2019	Jul 25, 2025	Coronary Heart Disease (CHD)
NCT03433755	Phase 3	Terminated	May 9, 2019	May 9, 2020	Primary Hypercholesterolemia
NCT03515304	Phase 2	Completed	May 20, 2018	Mar 25, 2025	Acute Coronary Syndrome
NCT02833844	Phase 3	Completed	May 22, 2017	Jan 27, 2020	Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
NCT02729025	Phase 3	Completed	Apr 14, 2016	Apr 5, 2018	Subjects With Hyperlipidemia, Dyslipidemia
NCT02392559	Phase 3	Completed	Mar 24, 2016	Nov 25, 2019	Heterozygous Familial Hypercholesterolemia
NCT01813422	Phase 3	Completed	Apr 18, 2013	Jul 29, 2016	Hypercholesterolemia
NCT01764633	Phase 3	Completed	Feb 8, 2013	Nov 11, 2016	Dyslipidemia
NCT01763918	Phase 3	Completed	Feb 7, 2013	Dec 19, 2013	Hyperlipidemia
NCT01588496	Phase 2/3	Completed	Apr 5, 2012	Jan 31, 2014	Homozygous Familial Hypercholesterolemia
NCT01375751	Phase 2	Completed	Aug 2, 2011	May 16, 2012	Hypercholesterolemia, Familial
NCT01133522	Phase 1	Completed	Jun 1, 2010	Sep 14, 2011	Hyperlipidemia

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40
Inclisiran + Placebo	Novartis	Phase 3	47
Bococizumab (PF-04950615;RN316)	Pfizer	Phase 3	40
Atorvastatin + Atorvastatin	Pfizer	Phase 1	29
IBI306 + placebo	Innovent Biologics	Phase 3	40
Lumacaftor Plus Ivacaftor Combination + Ivacaftor	Vertex Pharmaceuticals	Phase 3	40
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo	Sanofi	Phase 3	40
Placebo + Alirocumab	Sanofi	Phase 3	40
Praluent	Sanofi	Approved	35
AK102 + Placebo + Statins and/or Ezetimibe	Akeso	Phase 2	35
lerodalcibep	Medpace	Phase 3	37
mipomersen sodium + placebo	Ionis Pharmaceuticals	Phase 3	37
MGL-3196 (resmetirom) + Placebo	Madrigal Pharmaceuticals	Phase 2	32